- Real-world evidence from the 2025 EULAR Congress indicates potential benefits of GLP-1 receptor agonists in reducing symptom burden for patients with fibromyalgia.
- The analysis used data from the TriNetX research network to compare large patient cohorts over a 5-year follow-up period.
- GLP-1 receptor agonists showed potential in reducing opioid use, chronic pain, fatigue, and ongoing fibromyalgia care.
- The observational design limits causal conclusions, highlighting the need for further evaluation through randomized controlled trials.
GLP-1 Use Associated with Less Pain, Fatigue
Conexiant
June 19, 2025